SCIENTEX Information

The objective of SCIENTEX is to allow its clients to enjoy its experience from science to stock exchange, in order to serve them, the most effectively possible at corporate level. After a first R&D experience on radiopharmaceuticals at AREVA / CEA in 1993, Tim Muller worked as a pre-clinical pharmacochemist for the pharmaceutical industry (SERVIER) during 5 years on diabete mellitus & CNS up to proof of concept. Then Tim moved in 1999 to the private equity industry (CDC enterprises & Sofimac Partners) investing in 17 healthcare private companies (7 were acquired by industrials & 4 IPOs). Tim was an active non executive board member on 22 healthcare companies in Europe. Tim created then SCIENTEX in 2006 in order to act as a day to day transition manager in business & corporate development, and M&A (buy side & sell side) for small and medium healthcare companies, while he was advising in parallel wealthy individuals on VIX trading & working with secondary private equity funds. After +26 corporate development missions through Scientex in 6 years, Tim joined CROSSJECT in 2012 (see profile) during its restart in order to drive the new business & corporate development. Then, after the succesfull completion of a 472M$ licensing deal; Tim, in its position of member of the executive board, lead the $6M refinancing closed in june 2013, manage M&A opportunities & engage the IPO process, successfully oversubscribed 4,4 x in february 2014 (Photo1 & Photo2). Globally, Tim has been involved in + 95 corporate and business transactions, including 5 IPOs and 9 M&A. Berenice Muller, associate founding partner, PharmD (2001) & Master degree in Medtech, is developing Scientex offer’s in business development towards European SME in order to cover deeply the French market, while Tim focuses on international operations.